By IPOMarket Editorial Team · Last reviewed: May 2026
Disclaimer: This article is for informational purposes only and does not constitute investment advice. IPO investments are subject to market risks. Please read the offer document carefully and consult a SEBI-registered investment advisor before investing.
Surgiwear — a Uttar Pradesh-based domestic manufacturer of medical implantable devices and surgical disposables — received SEBI approval on May 4, 2026 for an IPO of approximately ₹740 crore, comprising a ₹370 crore fresh issue and a ₹370 crore OFS by promoter Ghanshyam Das Agarwal. The DRHP was filed on December 30, 2025. With India's medical-devices market on a structural growth trajectory and the Centre's PLI scheme actively supporting domestic manufacturing, Surgiwear offers retail investors exposure to a high-growth import-substitution play.
This review covers the issue structure, business profile, the medical-devices sector tailwind, strengths, risks and a decision framework for prospective investors.
Surgiwear IPO — Key Details at a Glance
| Detail | Information |
|---|---|
| Company | Surgiwear Ltd. |
| IPO Status | SEBI Approved |
| SEBI Approval Date | May 4, 2026 |
| DRHP Filed | December 30, 2025 |
| Fresh Issue | ₹370 crore |
| OFS | ₹370 crore (promoter Ghanshyam Das Agarwal) |
| Total Size | ~₹740 crore |
| Headquarters | Uttar Pradesh |
| Sector | Medical Devices |
| Listing | BSE and NSE Mainboard |
| GMP Today | Check live IPO GMP → |
About Surgiwear
Surgiwear is a leading domestic manufacturer of medical implantable devices and surgical disposables. The product portfolio spans:
- Orthopaedic implants — bone plates, screws, intramedullary nails and other trauma and joint reconstruction hardware used in fracture fixation and orthopaedic surgery.
- Hydrocephalus shunts — implantable medical devices used in neurosurgery (see FAQ for a plain-English explanation).
- Sterile surgical drapes — single-use sterile barriers used in operating theatres to maintain a sterile field around the surgical site.
- Other implantable devices across multiple surgical specialties.
The company is headquartered in Uttar Pradesh and is one of the larger Indian-owned domestic manufacturers in a market historically dominated by global MedTech imports.
Sector Context — India's Medical Devices Tailwind
The Indian medical devices market is in the early stages of a structural multi-year growth phase:
Market size and growth. India's medical devices market is currently approximately $11 billion and is projected to reach $50 billion by 2030 — a step-change in scale driven by rising healthcare spending, hospital infrastructure expansion and demographic ageing.
Government PLI scheme for medical devices. The Production Linked Incentive scheme for medical devices specifically targets domestic manufacturing of high-value implants, diagnostics and electronics. Domestic manufacturers like Surgiwear are direct PLI beneficiaries.
Import substitution opportunity. India currently imports 75%+ of its medical devices — a structural deficit that the government is actively trying to address. Domestic manufacturers in implantables, disposables and electronics have a multi-year tailwind from import substitution.
Hospital infrastructure expansion. Listed hospital chains (Apollo, Fortis, Max, Manipal, Narayana Hrudayalaya) and large standalone players continue to expand bed capacity. Each new hospital bed creates incremental demand for implants and surgical disposables.
The competitive landscape includes global MedTech majors (Stryker, Zimmer Biomet, Smith & Nephew, J&J/DePuy Synthes) and a small set of Indian-owned manufacturers.
Use of Proceeds
The fresh issue of ₹370 crore is expected to fund:
- Purchase of machinery — capacity expansion in implant manufacturing.
- Debt repayment.
- General corporate purposes.
The OFS of ₹370 crore is by promoter Ghanshyam Das Agarwal — meaning approximately 50% of the total issue size is OFS.
Investment Strengths
- Domestic manufacturing in a high-growth import-substitution segment. A structural multi-year tailwind from market growth + import substitution + PLI.
- PLI beneficiary. Direct policy support reduces effective cost of manufacturing and improves margin profile.
- Diversified product portfolio. Orthopaedic implants + neurosurgery shunts + surgical drapes + other implantables reduces single-product concentration risk.
- Uttar Pradesh manufacturing base. Lower labour cost and proximity to major North Indian hospital markets.
- Capacity expansion-led growth. Use of proceeds includes machinery purchase, directly funding incremental capacity to meet growing demand.
Risks & Concerns
- OFS = ~50% of total issue. Promoter Ghanshyam Das Agarwal is selling ₹370 Cr of stock — half of the issue size. Significant promoter dilution at IPO is typically read cautiously by institutional investors.
- Regulatory approval risk. New product launches require regulatory approval (CDSCO domestically, FDA/CE for exports). Approval delays can defer revenue.
- Competition from imported devices and global MedTech. Stryker, Zimmer Biomet, Smith & Nephew and J&J/DePuy dominate premium segments globally and have strong brand presence in Indian tertiary-care hospitals. Surgiwear competes primarily on price-and-availability rather than premium brand.
- Hospital procurement cycles. Large hospitals procure implants through long evaluation cycles. New entrant adoption is slow even when product quality and price are competitive.
- Quality and recall risk. Medical device recalls (a known industry-wide risk) can cause material reputational and financial damage.
Should You Apply for Surgiwear IPO?
A sensible decision framework when the IPO opens:
- Read the RHP carefully. Pay particular attention to product mix (implants vs disposables), gross-margin trajectory, hospital-customer concentration, export revenue share and the regulatory pipeline.
- Compare with listed medical-devices peers. Poly Medicure, Yatharth Hospital, Healthium MedTech (recently delisted) and global comparables provide useful multiple anchors.
- Question the OFS structure. A 50% OFS deserves a careful read of the promoter's post-listing skin-in-the-game.
- Watch the GMP. Track live IPO GMP once available.
- Apply at cut-off. Maximises retail allotment probability.
- Treat as a 3-5 year medical-devices theme. The Indian medical-devices growth and import-substitution thesis plays out over multiple years.
How to Track Surgiwear IPO Updates
We track every SEBI-approved IPO on our upcoming IPOs in 2026 page. For the broader pipeline, see our top upcoming IPOs 2026 watchlist.
How to Apply for Surgiwear IPO
Once the IPO opens, you can apply through any SEBI-registered broker:
Frequently Asked Questions
When will Surgiwear IPO open? SEBI approval was granted on May 4, 2026. Issuers typically launch within 3-9 months of SEBI nod. The exact open date will be confirmed in the RHP.
What is Surgiwear IPO size? The IPO is approximately ₹740 crore total — a ₹370 crore fresh issue plus a ₹370 crore offer-for-sale by promoter Ghanshyam Das Agarwal.
What are hydrocephalus shunts? Hydrocephalus is a medical condition in which excess cerebrospinal fluid (CSF) accumulates inside the cavities of the brain, causing increased pressure that can damage brain tissue. A hydrocephalus shunt is a small implantable medical device — essentially a thin tube with a one-way valve — that a neurosurgeon places to drain the excess fluid from the brain to another part of the body (usually the abdomen) where the body can absorb it safely. Shunts are life-saving devices and are one of the most common neurosurgical implants used worldwide. Manufacturing them requires precision engineering, biocompatible materials and rigorous quality control — Surgiwear is one of the few Indian-owned manufacturers with this capability.
What is the medical-devices sector outlook? India's medical-devices market is approximately $11 billion today and projected to reach $50 billion by 2030. The sector benefits from market growth, the PLI scheme, import substitution (India currently imports 75%+ of medical devices), and continued hospital infrastructure expansion.
Why is the OFS so large? The OFS by promoter Ghanshyam Das Agarwal is approximately ₹370 crore — about 50% of the total issue size. While significant promoter OFS at IPO can sometimes be a yellow flag, in this case it represents a partial monetisation by a long-term family promoter and not a full exit.
What is Surgiwear IPO GMP today? GMP is only quoted once an IPO is officially priced. Track the live IPO GMP page for currently active IPOs.
Last reviewed: May 2026 by IPOMarket Editorial Team. We update this page when the RHP is filed or the open date is announced.